Karus Therapeutics Commences Preclinical Development of Novel Immune and Inflammation Programmes
Karus Therapeutics Ltd has commenced preclinical development of its HDAC6 and PI3-Kinase inhibitor programmes for the treatment of immune and inflammatory diseases such as rheumatoid arthritis (RA). Karus aims to initiate clinical trials for both programmes in 2011.
Karus’s highly potent and selective small molecule inhibitors of HDAC6 and PI3-Kinase p110-delta regulate T-helper 17 (Th17) cell function and inhibit the production of interleukins 17, 21 and 23 (IL-17, IL-21, IL-23). Th17 cells play a key role in the pathogenesis of immune and inflammatory diseases such as RA, multiple sclerosis, psoriasis, systemic lupus erythematosus and organ transplant rejection. Karus’s compounds have been shown to inhibit the production of Th17 cell pro-inflammatory cytokines and, in preclinical models of RA, display efficacy comparable to the anti-TNF biologics.
Simon Kerry, CEO of Karus Therapeutics said: “There is a significant opportunity for the development of an important new class of anti-inflammatory drugs which selectively target Th17 cells via a novel mechanism of action. We are very excited by the potential of our development candidates as oral treatments for RA and other inflammatory diseases.”
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
AM-Pharma presents positive Phase II results for potential First-In-Class drug - Alkaline Phosphatase improved renal function, reduced length of stay in Intensive Care, and could become First-in-Class drug in multi-billion market
Ebola
Heart-muscle patches made with human cells improve heart attack recovery
Evotec and Boehringer Ingelheim Significantly Expand and Extend their Joint Drug Discovery Collaboration
Category:Johnson_&_Johnson
First comprehensive survey of gut, mouth and arterial bacteria finds links to heart disease

Unraveling key determinant of successful therapeutic vaccination against chronic hepatitis B

Malaria: It’s all about the mosquito - The relative frequency of two mosquito species determines the risk of transmission to humans
Category:Genes_on_chromosome_18
